Introduction
============

Research into symptoms experienced by patients with chronic kidney disease (CKD) has tended to focus on those with end-stage renal disease on dialysis, but evidence suggests that patients with advanced CKD (Stages 4--5) who are not requiring renal replacement therapy (RRT) report similar numbers of symptoms of comparable severity \[[@sfx057-B1]\]. Symptoms are often extremely debilitating and negatively impact quality of life (QoL) \[[@sfx057-B10]\]. Reduced QoL has been shown even in early stages of CKD (i.e. Stages 1--3) \[[@sfx057-B11]\], however little research has been carried out to assess symptom burden in patients with CKD Stages 1--5. A literature review by Almutary *et al.* in 2013 \[[@sfx057-B1]\] included six studies that quantitatively assessed the symptoms of CKD Stage 5 patients (not on RRT), of which two were palliative care studies \[[@sfx057-B5], [@sfx057-B6], [@sfx057-B8], [@sfx057-B9], [@sfx057-B12], [@sfx057-B13]\]. Only two of the studies included CKD Stage 4 patients for comparison with CKD Stage 5 and similar symptom profiles were observed between the two patient groups in both studies \[[@sfx057-B8], [@sfx057-B9]\].

Symptom burden and QoL of dialysis patients is associated with worsened hospitalization and mortality rates \[[@sfx057-B14]\]. In patients not on RRT, symptom and QoL assessments can be useful markers of clinical condition and disease progression \[[@sfx057-B15]\]. Therefore, their use is recommended to aid clinical decision- making such as timing of starting dialysis \[[@sfx057-B16]\]. Considering that the rising prevalence of CKD Stages 3--5 is currently estimated at 8.5% of the UK population, prevention strategies, informed decision-making and effective disease and symptom management are vital to maximize patient QoL and appropriately utilize finite resources in a growing CKD population \[[@sfx057-B17]\]. Furthermore, healthcare professionals often underestimate the symptom burden of their patients \[[@sfx057-B18]\]. One potential reason for this may be the lack of association between declining renal function and patient-reported symptoms as described in the current literature \[[@sfx057-B9], [@sfx057-B19], [@sfx057-B20]\]. However, this highlights the limitations of using laboratory results alone in patient assessment, and the importance of understanding and assessing symptomatology. The lack of routine and systematic symptom assessment has been formally recognized as a problem and described to the UK parliament as part of the Kidney Alliance: Delivering Excellence report in late 2013 \[[@sfx057-B21]\]"'Despite their importance, data on health-related QoL or symptom burden scores are not yet systematically collected or measured in UK renal centres, and this should be a focus of future activity for the UK Renal Registry. Patients with poor QoL and symptom scores must be recognised as being likely to have worse outcomes and managed appropriately.' \[[@sfx057-B21]\]."

Therefore, more research is required into the symptoms of CKD (throughout all stages) to appreciate the patterns and associations and to inform effective assessment, management and treatment of patients.

Furthermore, few studies have assessed symptom burden using a multidimensional tool to measure the prevalence, frequency and severity of symptoms reported by CKD patients \[[@sfx057-B1]\]. Only one previous study included patients not on RRT with CKD Stages 4--5 and assessed symptom burden using a multidimensional tool \[[@sfx057-B2]\]. The Leicester Uraemic Symptom Score (LUSS) is a symptom assessment tool that was originally designed by a renal clinician using observations of common symptoms reported by patients to use informally with dialysis patients. The LUSS has proved useful and sensitive to change in CKD patients not on RRT as an outcome measure to assess symptoms in exercise intervention studies \[[@sfx057-B22]\]. The LUSS assesses symptom burden by asking patients to rate the frequency and intrusiveness of 11 symptoms (Table [1](#sfx057-T1){ref-type="table"}). Table 1.Symptoms assessed as part of the LUSSLUSS symptomsItchingSleep disturbanceLoss of appetiteExcessive tirednessPain in bones/jointsPoor concentration/mental alertnessImpotence/lack of sex driveLoss of muscle strength/powerShortness of breathMuscle spasm/stiffnessRestless legs

This study aimed to explore symptom burden and potential contributing factors in patients with CKD Stages 1--5 not requiring RRT using the LUSS.

Materials and methods
=====================

Study design
------------

This cross-sectional study explored patient symptom burden using a self-completed questionnaire assessment.

Setting and participants
------------------------

Between July 2013 and August 2014, a convenience sample of adult patients attending outpatient clinics at the Leicester General Hospital were enrolled by researchers while waiting for appointments. All patients aged 18 years or over who were not currently requiring RRT and were able to communicate with the researchers (or with an interpreter) were eligible for inclusion. Patients willing to take part in the study were given the option to complete the symptom questionnaire and demographics questions anonymously, or to supplement this with consent to access of their relevant computerized medical records. This study was sponsored by the University Hospitals of Leicester NHS Trust (UHL) and approved by the East Midlands Research Ethics Committee -- Derby (Ref [@sfx057-B13]/EM/0155) and UHL Research and Development (Ref 11247).

Information from medical records
--------------------------------

For those who consented to their medical records being accessed, the most recently recorded blood test results were obtained from the electronic renal patient record. This included creatinine, bicarbonate, urea, albumin and calculated estimated glomerular filtration rate levels. All information was coded, anonymized and entered into the study database.

Symptom assessment
------------------

The LUSS was used for symptom assessment. The LUSS assesses the frequency (how often a patient experienced a symptom) and intrusiveness (how much a symptom affects a patient's life) of 11 symptoms, which are shown in Table [1](#sfx057-T1){ref-type="table"}. Frequency was assessed using the following response options: 'Never', 'Less than once a week', '1--2 times a week', 'Several times a week' and 'Every day', scored from 0 to 4. Intrusiveness was assessed with options of: 'Not applicable', 'Not at all intrusive', 'Slightly intrusive', 'Quite intrusive', 'Very intrusive' and 'Extremely intrusive', scored from 0 to 5. Space was also given for patients to write and rate any additional symptoms. Demographic questions were added to the questionnaire and ascertained the gender, age, ethnicity, comorbidities and time attending the clinic.

Statistical methods
-------------------

The demographic characteristics and comorbid health conditions were described and compared in patients reporting ≥6 and \<6 symptoms, using the chi-squared test for categorical variables (gender, ethnicity, CKD stage and time attending clinic) and two-sample *t*-test for continuous variables (age). P-values in Table [2](#sfx057-T2){ref-type="table"} refer to the comparison between patients \<6 and those with ≥6 symptoms. Table 2.Demographic characteristics and comorbid health conditions of participants by symptom reportingCharacteristicAll patients\<6 symptoms≥6 symptomsP-value[^a^](#tblfn1){ref-type="table-fn"}(*N* = 283)(*N* = 155)(*N* = 128)(%)(%)(%)Gender Male54.062.547.10.01 Female46.037.552.9Age ± standard error, years60.5 ± 1.059.8 ± 1.561.1 ± 1.40.53Ethnicity White71.072.070.30.77 South Asian21.219.522.6 Other7.88.67.1CKD stage[^b^](#tblfn2){ref-type="table-fn"} Stage 110.713.88.30.52 Stage 211.512.810.4 Stage 327.828.427.2 Stage 437.233.940.0 Stage 512.811.014.4Time attending clinic[^b^](#tblfn2){ref-type="table-fn"} \<1 year27.332.323.20.06 1--2 years18.818.119.4 3--5 years19.522.816.8 5+ years34.426.840.7Comorbid health conditions Diabetes: Type 12.62.72.50.65 Type 221.819.623.80.63 Other0.40.90.00.05 Hypertension68.567.069.90.82 Ischaemic heart disease14.59.818.90.70 Stroke/TIA3.93.64.10.51 Peripheral vascular disease6.05.46.60.33 Asthma/COPD10.311.69.00.36 Musculoskeletal disorders15.813.418.00.83 Neurological disorder1.70.892.46 Mental ill-health10.310.79.8[^1][^2][^3]

Symptoms were described and the total number of symptoms reported by CKD stage was plotted, with 95% confidence intervals.

Biochemical markers of disease severity were analysed in two ways: serum creatinine and blood urea nitrogen were treated as continuous variables, and serum bicarbonate and albumin categorized into normal and 'abnormal' levels (i.e. bicarbonate \<21 mEq/L and albumin \<40 g/L).

The relationship between intrusiveness of symptoms, creatinine and urea was studied using bivariate and multivariate ordered logistic regression models, adjusted for age, gender and/or ethnic group where significantly associated with the outcome variable. Because ordinal logistic regression assumes proportional odds, this assumption was tested using a likelihood ratio test and Brant test. Where either of these tests was violated, generalized ordered logistic regression models for ordinal outcome variables were fitted using the 'gologit2' command in Stata \[[@sfx057-B23]\]. Generalized ordered logistic regression takes account of ordering, but relaxes the proportional odds assumption in that larger values in the outcome variable are assumed to be 'higher', but the actual values are irrelevant \[[@sfx057-B23]\]. Estimated coefficients were transformed into relative odds ratios for ease of interpretation.

The relationship between abnormal bicarbonate, abnormal albumin levels and intrusiveness of symptoms was investigated using logistic regression modelling, adjusting for age, gender and/or ethnic group where significantly associated with the outcome variable. Linearity of intrusiveness of symptoms was evaluated using the Box-Tidwell test \[[@sfx057-B24]\] .

Results
=======

Participant characteristics
---------------------------

A total of 356 patients were approached in the clinic waiting room and the study was explained to them. Of these, 283 patients agreed to complete the questionnaire and the majority (236) also gave consent for access to their medical records for further information. This included details about recorded co-morbidities and prescribed medications, and the most recent results of commonly measured biochemical markers. The process is illustrated in Figure [1](#sfx057-F1){ref-type="fig"}.

![Flow chart of patient recruitment and involvement.](sfx057f1){#sfx057-F1}

The participant demographics are presented in Table [2](#sfx057-T2){ref-type="table"}. Just over half of participants were men and the majority (71%) were white. The mean age was 61 years old. Comorbid health conditions were common in this population: over two-thirds (69%) had hypertension, 25% had diabetes (22% type 2), 16% had musculoskeletal problems and 16% had ischaemic heart disease.

We compared the patients in our study with 8414 nephrology patients seen in 2013 and found that participants in this study were generally younger (mean age average 61 vs 64 years old; *t*-test P = 0.005), and were more likely to be of South Asian or other ethnic origin (11% vs 21% South Asian; and 3% vs 8% Other; chi^2^ P \< 0.001). The gender distribution of participants was relatively similar among participants and other general nephrology patients (51% vs 54% male; chi^2^ P = 0.33).

Symptoms reported
-----------------

The vast majority of patients (*N* = 272; 96%) reported at least one symptom, with only 11 (4%) patients describing no symptoms at all. The median number of symptoms reported was 6 (interquartile range 3--8). Men (P = 0.01) were more likely to report fewer than six symptoms than women.

Table [3](#sfx057-T3){ref-type="table"} shows the symptoms reported and their frequency/intrusiveness. Excessive tiredness was the symptom reported most often \[*n* = 224; 81% (76.0--85.6)\], on average (median) several times per week. This was followed by sleep disturbance \[*n* = 196; 70% (64.3--75.3)\], occurring on average (median) 1--2 times per week, and pain in the bones or joints \[*n* = 191; 69% (63.4--74.6)\], occurring on average less than once per week. Table 3.Symptoms[^a^](#tblfn4){ref-type="table-fn"} reported, their frequency and intrusiveness (*N* = 283)SymptomFrequency (%)Intrusiveness (%)ItchingNever51.6N/A47.7Less than once per week17.0Not at all10.31--2 times per week7.8Slightly17.3Several times per week7.4Quite7.8Every day12.7Very4.2--Extremely4.6Missing data3.5Missing data8.1Sleep disturbanceNever34.3N/A30.0Less than once per week9.9Not at all9.51--2 times per week10.6Slightly21.2Several times per week11.7Quite9.2Every day31.5Very12.7--Extremely10.6Missing data2.1Missing data6.7Loss of appetiteNever61.1N/A55.1Less than once per week12.4Not at all10.31--2 times per week6.4Slightly12.7Several times per week7.1Quite5.3Every day8.8Very4.2--Extremely1.8Missing data4.2Missing data10.6Excessive tirednessNever21.9N/A19.1Less than once per week9.9Not at all9.21--2 times per week16.6Slightly22.6Several times per week17.3Quite18.0Every day31.8Very13.4--Extremely8.8Missing data2.5Missing data8.8Pain in bones/jointsNever34.6N/A31.1Less than once per week14.8Not at all8.51--2 times per week7.4Slightly18.7Several times per week10.6Quite10.6Every day29.3Very14.8--Extremely7.4Missing data3.2Missing data8.8Poor concentration/mental alertnessNever55.1N/A52.7Less than once per week12.4Not at all6.71--2 times per week10.6Slightly15.6Several times per week7.4Quite6.7Every day9.2Very5.3--Extremely2.5Missing data5.3Missing data10.6Impotence/lack of sex driveNever44.5N/A58.0Less than once per week6.4Not at all6.71--2 times per week3.9Slightly5.0Several times per week3.9Quite5.3Every day13.1Very4.2--Extremely4.6Missing data28.3Missing data16.3Loss of muscle strength/powerNever41.0N/A36.4Less than once per week10.3Not at all6.71--2 times per week9.5Slightly19.4Several times per week9.2Quite9.5Every day24.0Very11.7--Extremely7.1Missing data6.0Missing data9.2Shortness of breathNever39.6N/A34.6Less than once per week11.3Not at all7.81--2 times per week10.3Slightly19.8Several times per week12.7Quite11.0Every day23.0Very9.9--Extremely7.4Missing data3.2Missing data9.5Muscle spasm/stiffnessNever42.1N/A38.9Less than once per week12.7Not at all9.21--2 times per week10.3Slightly18.4Several times per week14.5Quite9.9Every day16.3Very8.5Extremely5.0Missing data4.2Missing data10.3Restless legsNever48.4N/A44.9Less than once per week13.8Not at all11.01--2 times per week7.4Slightly13.1Several times per week12.4Quite8.1Every day15.2Very7.8--Extremely5.7Missing data2.8Missing data9.5[^4]

The median numbers of symptoms by CKD stage are shown in Figure [2](#sfx057-F2){ref-type="fig"}. There was a moderate trend in the number of symptoms by CKD stage (non-parametric test for trend P = 0.03).

![Median number of kidney symptoms reported in general nephrology patients by stage of CKD. IQR, interquartile range; *n* = 49 adults with unknown CKD stage excluded. Non-parametric test for trend for the ranks across ordered groups (extension of Wilcoxon rank-sum test) P = 0.03.](sfx057f2){#sfx057-F2}

Relationship between reporting of symptoms, their intrusiveness and biochemical markers of disease severity
-----------------------------------------------------------------------------------------------------------

The relationships between reporting of symptoms, their intrusiveness and biomarkers of disease severity are shown in Table [4](#sfx057-T4){ref-type="table"}. Table 4.Relationship between intrusiveness of symptoms, creatinine and urea levels (markers of disease severity)Proportional odds assumption heldProportional odds assumption violatedIncreasing intrusivenessN/A vs (NI, SI, QI, VI, EI)(N/A, NI) vs (SI, QI, VI, EI)(N/A, NI, SI) vs (QI, VI, EI)(N/A, NI, SI, QI) vs (VI, EI)(N/A, NI, SI, QI, VI) vs EISymptom*N*ORPORPORPORPORPORPItching[^a^](#tblfn6){ref-type="table-fn"}** Creatinine**217**1.0040.0011.0030.0021.0030.02**0.9990.85**1.0080.02 Urea**217**1.0520.0041.0510.0041.0500.03**1.0130.721.1180.13Sleep disturbance[^a^](#tblfn6){ref-type="table-fn"} Creatinine2231.0010.401.0010.451.0010.541.0000.981.0000.95 Urea2231.0240.241.0100.561.0060.720.9950.810.9880.67Loss of appetite[^b^](#tblfn7){ref-type="table-fn"}** Creatinine**213**1.0020.04 Urea**213**1.0410.01**Excessive tiredness[^b^](#tblfn7){ref-type="table-fn"}** Creatinine**215**1.0030.02**1.0020.131.0000.960.9990.24**0.9950.02** Urea2151.0080.55Pain in bones/joints[^c^](#tblfn8){ref-type="table-fn"} Creatinine2180.9990.250.9990.290.9980.091.0020.271.0010.67 Urea2180.9700.090.9880.510.9670.090.9950.840.9700.50Poor concentration/mental alertness[^c^](#tblfn8){ref-type="table-fn"} Creatinine2101.0000.741.0010.240.9970.130.9950.150.9830.15** Urea**2101.0150.401.0240.190.9610.12**0.8610.03**0.5870.10Impotence/lack of sex drive[^d^](#tblfn9){ref-type="table-fn"} Creatinine1991.0020.11** Urea**199**1.0430.02**Loss of muscle strength/power[^e^](#tblfn10){ref-type="table-fn"} Creatinine2151.0010.430.9990.451.0000.690.9990.360.9990.69 Urea2151.0260.171.0160.371.0050.790.9910.730.9720.49Shortness of breath Creatinine2131.0010.37 Urea2131.0190.20Muscle spasm/stiffness[^b^](#tblfn7){ref-type="table-fn"}** Creatinine**212**1.0020.04 Urea**212**1.0360.02**Restless legs Creatinine2141.0001.00 Urea2140.9950.76[^5][^6][^7][^8][^9][^10][^11]

A total of 7 of the 11 symptoms were found to be associated with creatinine and/or urea levels. These symptoms were: itching (creatinine and urea); loss of appetite (creatinine and urea); excessive tiredness (creatinine only); pain in bones/joints (albumin only); poor concentration/mental alertness (urea only); impotence/lack of sex drive (urea only); and muscle spasms/stiffness (creatinine and urea).

Individuals with raised creatinine levels were more likely to report itching, loss of appetite, muscle spasms/stiffness and excessive tiredness. The first three of these symptoms were also reported to be more intrusive in this group but, conversely, excessive tiredness was reported to be less intrusive. Urea levels followed a similar pattern: people with raised urea levels were more likely to report itching, loss of appetite, muscle spasms/stiffness and impotence/lack of sex drive. The latter three symptoms were also reported to be more intrusive in this group. However, people with raised urea levels tended to find symptoms of concentration/mental alertness less intrusive than those with lower levels. Similarly, people with abnormal albumin levels tended to find their pain in bones/joints less intrusive than those with normal levels.

Relationship between reporting of symptoms, their intrusiveness and demographic characteristics
-----------------------------------------------------------------------------------------------

Compared with women, men were less likely to report nearly all of the symptoms and, if they did report symptoms, they were less likely to find them intrusive. Older individuals were more likely to report pain in the bones/joints and loss of muscle strength and to report that they were intrusive symptoms; conversely, younger individuals were more likely to report lack of concentration/mental alertness and to report that this symptom was intrusive.

Compared with white or 'other' ethnic groups, individuals of South Asian origin were more likely to report intrusive pain in the bones/joints, but were less likely to report any problems with impotence/lack of sex drive. Adults from 'other ethnic' groups, the majority of whom (77%) were of Black African or Black Caribbean origin, were less likely to report itching and sleep disturbance but, if they were present, were more likely to find them intrusive. They were also more likely to report that poor concentration/mental alertness was an intrusive symptom.

Discussion
==========

CKD patients experience a reduced QoL even in early disease stages and symptom burden is a major contributing factor \[[@sfx057-B11]\]. Understanding the symptomatology of this patient group and gaining more insight into the pathophysiological processes could inform clinical management and improve patient QoL. This study explored the symptom burden of patients with CKD Stages 1--5 (not on RRT) in addition to the relationships between the reported symptoms and patient characteristics and biochemical results. We believe that this is the first study that assesses symptom burden in CKD patients Stages 1--5, as previous papers have focused on patients either on dialysis or with CKD Stages 4--5 \[[@sfx057-B1], [@sfx057-B2], [@sfx057-B8], [@sfx057-B9]\].

The vast majority of patients (96%) reported at least one symptom and we found a moderate association between the number of symptoms reported and worsening CKD stage. When symptoms were analysed individually, excessive tiredness was reported most commonly, followed by sleep disturbance and pain in the bones or joints. Our findings showed similarities to observations in two previous studies including CKD Stage 4 patients, as overviewed in the 2013 literature review by Almutary *et al.* \[[@sfx057-B1]\] . The most commonly reported physical symptoms were weakness (75%), poor mobility (75%), poor appetite (58%), pain (56%), pruritus (56%) and dyspnoea (49%) in one study \[[@sfx057-B8]\] and fatigue or lack of energy (78%), dry skin (53%), difficulty sleeping (44%), pruritus (44%), and bone or joint pain (39%) in the other study \[[@sfx057-B9]\]. As similar symptoms have been reported by patients with CKD Stages 1--5 in this study and in patients with CKD 4--5 in other studies \[[@sfx057-B8], [@sfx057-B9]\], this suggests that symptom assessment is appropriate and relevant even in early stages of the disease. In addition, the lack of a consistent relationship between symptoms and CKD stage highlights that it is difficult to predict symptomatology from renal function alone as found in other research studies \[[@sfx057-B9], [@sfx057-B19], [@sfx057-B20]\]. As a major contributing factor to QoL, focusing on reducing symptom burden by incorporating symptom assessment into clinical management and research in patients could address the issue of reduced QoL from earlier stages of CKD progression \[[@sfx057-B11]\].

Symptom reporting appeared to be related to certain demographic characteristics of the participants. Comparisons by gender showed that men were less likely to report symptoms and described them as less intrusive when they did report them. Differences observed between ethnic groups included South Asian patients tending to report more symptoms. Age comparisons showed variations in the intrusiveness of symptoms reported, with the older patients finding pain in the bones or joints and muscle weakness and younger people describing loss of concentration as more intrusive, respectively. While the odds ratios were small, we did observe statistically reliable associations between biochemical markers of disease burden and symptom severity. This is broadly consistent with other studies \[[@sfx057-B8], [@sfx057-B9], [@sfx057-B19]\].

Demographic characteristics need to be considered when interpreting the symptom reporting. Additionally, the relationship between the frequency and severity of reported symptoms need to be evaluated to better understand the impact on the individual patient. This requires a multidimensional approach. Further understanding and awareness of the factors and contributors to symptom burden has the potential to aid future clinical management.

There are limitations to the study. First, our patients were recruited from one centre and so may not reflect the general symptom burden of other CKD patients. Furthermore, the study sample comprised a relatively small number of patients and a relatively large number of statistical tests, increasing the likelihood of finding statistically significant results by chance alone. Although this cross-sectional study design provided a means of assessing reported symptoms over a range of CKD stages, we were unable to determine true associations between comorbidities and other possible confounding factors. In addition, although the convenience sampling method provided data from CKD Stages 1--5 patients, each CKD stage was not equally represented. Finally, the LUSS is an informally developed multidimensional tool that assesses the frequency and intrusiveness of 11 symptoms, and is currently not validated. Although it has been found useful previously when assessing symptoms \[[@sfx057-B22]\], no information is available on whether it is an appropriate measure of symptoms in the CKD Stages 1--5 population or if it includes the relevant symptoms. Work and improvements on the content, validity and design are required to use it as a tool in further research.

As the number of patients with CKD rises, it will become increasingly important to direct patient management services and research effectively. Exploration into the symptom burden of the CKD population is vital to addressing the patient experience and gaining further understanding of the disease. This study explored the impact of earlier disease stages and showed that patients report symptoms in CKD Stages 1--5. Symptom burden is multifactorial and subjective in nature and in this study we showed that factors including gender, ethnicity, age and disease severity may contribute to reported symptomatology. Therefore, it is difficult to use serological results in isolation as a predictor of patient well-being.

Practical implications
----------------------

The LUSS has proven to be useful in the assessment of the range, frequency and severity of symptoms reported by CKD patients. As shown within this manuscript, symptoms may vary. Our findings suggest that symptoms may change with disease progression and assessment of symptoms should be incorporated into clinical management and research even in the early stages of CKD. This research explores the symptoms that patients with CKD Stages 1--5 experience to further inform the development of an appropriate symptom assessment tool. International guidelines recommend that the presence of symptoms attributable to kidney failure be taken into account when timing the initiation of RRT \[[@sfx057-B16]\]. However, no validated symptom questionnaire is widely accepted to assess disease progression and variety by patient group, and for assessment. This area has been highlighted for future development \[[@sfx057-B21]\]. The LUSS may provide a useful, multidimensional tool for measuring patient symptom burden and further work has been undertaken to improve and validate the measure.

In conclusion, it is well understood that patients in the later stages of CKD requiring RRT and also those treated conservatively experience a wide range of symptoms, and therefore have reduced QoL \[[@sfx057-B1]\]. Our findings suggest that patients with CKD Stages 1--5 suffer from a multitude of symptoms. Using multidimensional tools like the LUSS, more exploration and focus should be given to address symptom burden at an earlier stage in our growing CKD population.
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[^1]: Chi-squared P-value for categorical variables; two-sample *t*-test for continuous variables.

[^2]: Percentages exclude missing values for CKD stage (*n *=* *49), time attending clinic (*n *=* *1) and comorbid health conditions (*n *=* *48 for hypertension; *n *=* *49 for diabetes, ischaemic heart disease, peripheral vascular disease, asthma/COPD, musculoskeletal disorders, neurological disorders and mental ill-health; *n *=* *50 for stroke/TIA).

[^3]: TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease.

[^4]: A total of 142 (50%) individuals reported other symptoms. Symptoms varied, but were most commonly frequent urination/nocturia (*n* = 51), pain (*n* = 27), back pain (*n* = 10), feeling cold (*n* = 21), cramps (*n* = 13) and nausea (*n* = 10).

[^5]: *N*, number of patients; OR, odds ratio; P, P-value; N/A, not applicable (i.e. no symptoms); NI, not at all intrusive, SI, slightly intrusive; QI, quite intrusive; VI, very intrusive; EI, extremely intrusive.

[^6]: Adjusted for gender and ethnicity.

[^7]: Adjusted for gender only.

[^8]: Adjusted for age, gender and ethnicity.

[^9]: Adjusted for ethnicity only.

[^10]: Adjusted for age and ethnicity.

[^11]: The bold figures in this table denote statistically significant relationships between symptoms and markers of disease severity.
